ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2012--
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic
products for unmet eye care needs, today announced that the company’s
Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time
on Thursday, May 31, 2012, for shareholders of record on April 6, 2012.
The Annual Meeting will be held at InSite Vision’s headquarters at 965
Atlantic Avenue, Alameda, California. InSite Vision plans to mail the
definitive proxy statement for the Annual Meeting, as well as its annual
report, in mid-April.
About InSite Vision
InSite Vision is advancing new and superior ophthalmologic products for
unmet eye care needs. The company’s product portfolio utilizes InSite
Vision’s proven DuraSite® bioadhesive polymer core
technology, an innovative platform that extends the duration of drug
retention on the surface of the eye, thereby reducing frequency of
treatment and improving the efficacy of topically delivered drugs. The
DuraSite platform is currently leveraged in two commercial products for
the treatment of bacterial eye infections, AzaSite®
(azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck,
and Besivance® (besifloxacin ophthalmic suspension) 0.6%,
marketed globally by Bausch + Lomb. InSite Vision’s clinical-stage
ophthalmic product pipeline includes AzaSite Plus™ and
DexaSite™ for the treatment of eye infections, BromSite™
(ISV-303) for pain and swelling associated with ocular surgery, and
ISV-101 for the treatment of dry eye disease. For further information on
InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb
Source: InSite Vision Incorporated
Louis Drapeau, 510-747-1220
Michelle Corral, 415-794-8662